Carotenoid ester analogs or derivatives for controlling connexin 43 expression
Abstract
A method of controlling (e.g., influencing or affecting) connexin 43 expression in a subject may include administering to the subject an effective amount of a pharmaceutically acceptable formulation. In some embodiments, controlling connexin 43 expression in a subject may effectively treat cardiac arrhythmia and/or cancerous and pre-cancerous cells in a subject. The pharmaceutically acceptable formulation may include a synthetic analog or derivative of a carotenoid. The subject may be administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include a cyclic ring including at least one substituent. In some embodiments, a cyclic ring of a carotenoid analog or derivative may include at least one substituent. The substituent may be coupled to the cyclic ring with an ester functionality.
Claims
exact text as granted — not AI-modified1 - 2022 . (cancelled)
2023 . A method of controlling connexin 43 expression in a subject comprising administering to the subject an effective amount of a pharmaceutically acceptable formulation comprising a synthetic carotenoid analog or derivative;
wherein the synthetic analog or derivative of the carotenoid has the structure: where z is from 5 to 12; where each R 3 is independently hydrogen or methyl; where each Y is independently O or H 2 ; where each R is independently OR 1 or R 1 ; where each R 1 is independently-alkyl-NR 2 3 + , -aromatic-NR 2 3 + , -alkyl-CO 2 − , -aromatic-CO 2 − , -amino acid-NH 3 + , -phosphorylated amino acid-NH 3 + , polyethylene glycol, dextran, H, alkyl, or aryl; and where each R 2 is independently H, alkyl, or aryl.
2024 . The method of claim 2023 , wherein the carotenoid analog or derivative is at least partially water soluble.
2025 . The method of claim 2023 , wherein Y is H 2 , and wherein the carotenoid analog or derivative has the structure
2026 . The method of claim 2023 , wherein Y is O, and wherein the carotenoid analog or derivative has the structure
2027 . The method of claim 2023 , wherein the carotenoid analog or derivative further comprises at least one chiral center.
2028 . The method of claim 2023 , wherein the carotenoid analog or derivative is a analog or derivative of a naturally occurring carotenoid.
2029 . The method of claim 2023 , wherein the carotenoid analog or derivative is a analog or derivative of a naturally occurring carotenoid, and wherein the naturally occurring carotenoid is astaxanthin, beta-carotene, lutein, zeaxanthin, or canthaxanthin.
2030 . The method of claim 2023 , wherein the carotenoid analog or derivative has the structure
where each X is independently -alkyl-NR 4 3 + , -aromatic-NR 4 3 + , -alkyl-CO 2 − , -aromatic-CO 2 − , -amino acid-NH 3 + , -phosphorylated amino acid-NH 3 + , polyethylene glycol, dextran, H, alkyl, or aryl, and where each R 4 is independently H, alkyl, or aryl;
where each R′ is independently -alkyl-O, alkyl, or aryl; and
where n is between 0 and about 12.
2031 . The method of claim 2023 , wherein the carotenoid analog or derivative has the structure
where each X is independently -alkyl-NR 4 3 + , -aromatic-NR 4 3 + , -alkyl-CO 2 − , -aromatic-CO 2 − , -amino acid-NH 3 + , -phosphorylated amino acid-NH 3 + , polyethylene glycol, dextran, H, alkyl, or aryl, and where each R 4 is independently H, alkyl, or aryl;
where each R′ is independently -alkyl-O, alkyl, or aryl; and
where n is between 0 and 12.
2032 . The method of claim 2023 , wherein the carotenoid analog or derivative has the structure
2033 . The method of claim 2023 , wherein the carotenoid analog or derivative has the structure
2034 . The method of claim 2023 , wherein the carotenoid analog or derivative has the structure
2035 . The method of claim 2023 , wherein the carotenoid analog or derivative has the structure
2036 . The method of claim 2023 , wherein the carotenoid analog or derivative has the structure
2037 . The method of claim 2023 , wherein the carotenoid analog or derivative has the structure
2038 . The method of claim 2023 , wherein the carotenoid analog or derivative has the structure
2039 . The method of claim 2023 , wherein the carotenoid analog or derivative has the structure
2040 . The method of claim 2023 , wherein the carotenoid analog or derivative has the structure
2041 . The method of claim 2023 , wherein the carotenoid analog or derivative has the structure
2042 . The method of claim 2023 , wherein the carotenoid analog or derivative has the structure
2043 . The method of claim 2023 , wherein the carotenoid analog or derivative has the structure
2044 . The method of claim 2023 , wherein the carotenoid analog or derivative has the structure
2045 . The method of claim 2023 , wherein the carotenoid analog or derivative has the structure
2046 . The method of claim 2023 , wherein the carotenoid analog or derivative has the structure
2047 . The method of claim 2023 , wherein the carotenoid analog or derivative has the structure
2048 . The method of claim 2023 , wherein the carotenoid analog or derivative has the structure
2049 . The method of claim 2023 , wherein the carotenoid analog or derivative has the structure
2050 . The method of claim 2023 , wherein the carotenoid analog or derivative has the structure
2051 . The method of claim 2023 , wherein the carotenoid analog or derivative has the structure
2052 . The method of claim 2023 , wherein the carotenoid analog or derivative has the structure
2053 . The method of claim 2023 , wherein the carotenoid analog or derivative has the structure
2054 . The method of claim 2023 , wherein the carotenoid analog or derivative has the structure
2055 . The method of claim 2023 , wherein the carotenoid analog or derivative has the structure
2056 . The method of claim 2023 , wherein the carotenoid analog or derivative has the structure
2057 . The method of claim 2023 , wherein the carotenoid analog or derivative has the structure
2058 . The method of claim 2023 , wherein the carotenoid analog or derivative has the structure
2059 . The method of claim 2023 , wherein the carotenoid analog or derivative has the structure
2060 . The method of claim 2023 , wherein the carotenoid analog or derivative has the structure
2061 . The method of claim 2023 , wherein the carotenoid analog or derivative has the structure
2062 . The method of claim 2023 , wherein the carotenoid analog or derivative is at least partially water dispersible.
2063 . The method of claim 2023 , wherein each R 1 is independently
2064 . The method of claim 2023 , wherein the subject is a mammal.
2065 . The method of claim 2023 , wherein the subject is human.
2066 . The method of claim 2023 , wherein administering the pharmaceutically acceptable formulation to a subject comprises administering the pharmaceutically acceptable formulation to a subject parenterally.
2067 . The method of claim 2023 , wherein administering the pharmaceutically acceptable formulation to a subject comprises administering the carotenoid analog or derivative to a subject parenterally at a dose of about 5 mg to about 300 mg per day.
2068 . The method of claim 2023 , wherein administering the pharmaceutically acceptable formulation to a subject comprises administering the carotenoid analog or derivative to a subject parenterally at a dose of about 0.25 mg to about 1.0 g per day.
2069 . The method of claim 2023 , wherein administering the pharmaceutically acceptable formulation to a subject comprises intracoronary administration of the pharmaceutically acceptable formulation to a subject.
2070 . The method of claim 2023 , wherein administering the pharmaceutically acceptable formulation to a subject comprises intracoronary administration of the carotenoid analog or derivative to a subject at a dose of about 5 mg to about 300 mg per day.
2071 . The method of claim 2023 , wherein administering the pharmaceutically acceptable formulation to a subject comprises intracoronary administration of the carotenoid analog or derivative to a subject at a dose of about 0.25 mg to about 1.0 g per day.
2072 . The method of claim 2023 , wherein administering pharmaceutically acceptable formulation to a subject comprises administering the pharmaceutically acceptable formulation to a subject subcutaneously.
2073 . The method of claim 2023 , wherein administering the pharmaceutically acceptable formulation to a subject comprises administering the carotenoid analog or derivative to a subject orally.
2074 . The method of claim 2023 , wherein administering the pharmaceutically acceptable formulation to a subject comprises administering the carotenoid analog or derivative to a subject orally at a dose of about 5 mg to about 100 mg per day.
2075 . The method of claim 2023 , wherein administering the pharmaceutically acceptable formulation to a subject comprises administering the carotenoid analog or derivative to a subject orally at a dose of about 0.25 mg to about 1.0 g per day.
2076 . The method of claim 2023 , wherein administering the pharmaceutically acceptable formulation to a subject comprises administering the carotenoid analog or derivative at a dose in a range of about 0.25 mg to about 1 g.
2077 . The method of claim 2023 , wherein administering the pharmaceutically acceptable formulation to a subject comprises administering at least two different carotenoid analog or derivatives.
2078 . The method of claim 2023 , wherein administering the pharmaceutically acceptable formulation reduces the numberof cancerous and pre-cancerous cells.
2079 . The method of claim 2023 , wherein administering the pharmaceutically acceptable formulation reduces the numberof cancerous cells, wherein cancerous cells comprise carcinogen-initiated cell.
2080 . The method of claim 2023 , further comprising controlling intercellular gap junctional communication.
2081 . The method of claim 2023 , further comprising treating cardiac arrhythmia.
2082 . The method of claim 2023 , wherein administering the pharmaceutically acceptable formulation to a subject comprises administering the carotenoid analog or derivative to a subject in the form of an emulsion.
2083 . The method of claim 2023 , wherein administering the pharmaceutically acceptable formulation to a subject comprises administering the pharmaceutically acceptable formulation to a subject in the form of an emulsion comprising water, oil and lecithin.
2084 . The method of claim 2023 , wherein administering the pharmaceutically acceptable formulation to a subject comprises a direct relationship between the amount of the carotenoid analog or derivative administered and an effect of the administered carotenoid analog or derivative.
2085 . The method of claim 2023 , further comprising inhibiting at least some of the substantially negative consequences of a disease state.
2086 . The method of claim 2023 , further comprising reducing at least some of the substantially negative consequences of a disease state.
2087 . The method of claim 2023 , wherein the carotenoid analog or derivative may decompose during use, wherein one or more of the products of the decomposition may be more biologically active relative to the carotenoid analog or derivative.
2088 . The method of claim 2023 , further comprising administering a co-antioxidant.
2089 . A method of treating cardiac arrhythmia in a subject comprising administering to the subject an effective amount of a pharmaceutically acceptable formulation comprising a synthetic carotenoid analog or derivative;
wherein the synthetic analog or derivative of the carotenoid has the structure: where z is from 5 to 12; where each R 3 is independently hydrogen or methyl; where each Y is independently O or H 2 ; where each R is independently OR 1 or R 1 ; where each R 1 is independently -alkyl-NR 2 3 + , -aromatic-NR 2 3 + , -alkyl-CO 2 − , -aromatic-CO 2 − , -amino acid-NH 3 + , -phosphorylated amino acid-NH 3 + , polyethylene glycol, dextran, H, alkyl, or aryl; and where each R 2 is independently H, alkyl, or aryl.
2090 - 2153 . (cancelled)
2154 . A method of treating cancerous and pre-cancerous cells in a subject comprising administering to the subject an effective amount of a pharmaceutically acceptable formulation comprising a synthetic carotenoid analog or derivative;
Wherein the synthetic analog or derivative of the carotenoid has the structure: where z is from 5 to 12; where each R 3 is independently hydrogen or methyl; where each Y is independently O or H 2 ; where each R is independently OR 1 or R 1 ; where each R 1 is independently -alkyl-NR 2 3 + , -aromatic-NR 2 3 + , -alkyl-CO 2 − , -aromatic-CO 2 − , -amino acid-NH 3 + , -phosphorylated amino acid-NH 3 + , polyethylene glycol, dextran, H, alkyl, or aryl; and where each R 2 is independently H, alkyl, or aryl.
2155 - 2529 . (cancelled)Join the waitlist — get patent alerts
Track US2005009788A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.